Proteasome inhibitors: A new perspective for treating autoimmune diseases

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1665-1675

  Fierabracci, Alessandra ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Autoimmunity; Immunoproteasome; Novel therapeutics; Proteasome inhibitors; Treatment; Ubiquitin proteasome system

Indexed keywords

1, 4 NAPHTHOQUINONE DERIVATIVE; AUTOANTIBODY; AZATHIOPRINE; BELIMUMAB; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DELANZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INORGANIC COMPOUND; MACROCYCLIC COMPOUND; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEDD8 INHIBITOR; NEDD8 PROTEIN; ONX 0914; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN E1 INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; ENCEPHALOMYELITIS; ENTERITIS; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HASHIMOTO DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; POLYNEUROPATHY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; BORONIC ACIDS; HUMANS; PROTEASOME INHIBITORS; PYRAZINES; TREATMENT OUTCOME;

EID: 84870227323     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530053     Document Type: Article

References (101)

1. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Ann Rev Biochem 2009; 78: 477-513.
2. De Bettignies G, Coux O. Proteasome inhibitors: dozens of molecules and still counting. Biochimie 2010; 92: 1530-1545.
3. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 2006; 145: 676-684.
4. Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci USA 1977; 74: 54-58.
5. Goldberg AL, Rock K. Not just research tools- proteasome inhibitors offer therapeutic promise. Nat Med 2002; 8: 338-340.
6. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 1964-1979.
7. Krahn D, Ottmann C, Kaiser M. Macrocyclic proteasome inhibitors. Curr Med Chem 2011; 18: 5052-5060.
8. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15: 243-249.
9. Fierabracci A, Milillo AM, Locatelli F, Fruci D. The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: insights from genomic-wide association studies. Autoimmun Rev 2012; doi:10.1016/J.autrev.2012.04.007.
10. Groll M, Ditzel L, Lowe, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386: 463-471.
11. Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digest of enolase I. Proc Natl Acad Sci USA 1998; 95: 12504-12509.
12. Van Deventer S, Neefjes J. The immunoproteasome cleans up after inflammation. Cell 2010; 142: 517-518.
13. Groettrup M, Khan S, Schwarz K, Schmidtke G. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie 2001; 83: 367-372.
14. DeMartino GN, Slòaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274: 22123-22126.
15. Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 1998; 187: 97-104.
16. Murata S, Sasaki K, Kishimoto T, et al. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 2007; 316: 1349-1353.
17. Chari A, Mazymber A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 2010; 4: 273-287.
18. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Pulmonary manifestations of systemic autoimmune diseases. Maedica 2011; 6:224-229.
19. Fierabracci A, Ayroldi E. Experimental strategies in autoimmunity: antagonists of cytokines and their receptors, nanocarriers, inhibitors of immunoproteasome, leukocyte migration and protein kinases. Curr Pharm Des 2011; 17:3094-3107.
20. Rosado MM, Diamanti AP, Capolunghi F, Carsetti R. B cell modulation strategies in autoimmunity: the SLE example. Curr Pharm Des 2011; 17: 3155-3165.
21. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008; 17: 426-430.
22. Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol 2012; 12: 257-270.
23. Neubert K, Meister S, Moser K. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755.
24. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-290.
25. Maseda D, Meister S, Neubert K, Hermann M, Voll RE. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008; 15: 600-612.
26. Hainz N, Thomas S, Neuvert K, et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nepron Exp Nephrol 2012; 120: e47-e58.
27. Bontscho J, Schreiber A, Manz RA, et al. Myeloperoxidasespecific plasma cell depletion by bortezomib protects from antineutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22; 336-348.
28. Brandoo FM, Coelho P, Pinto P, Compe B. A new step in rheumatoid arthritis treatment. Acta Rheumatol Port 2010; 35: 302-312.
29. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
30. McInnes IB, O'Dell JR. State of the art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-1906.
31. Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1: 102-110.
32. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739-758.
33. Cromartie WJ, Craddock JC, Schwab JH, Anderie SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977; 146: 1585-1602.
34. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1988; 95: 15671-1566.
35. Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009; 68: 1761-1767.
36. Yanaba K, Asana Y, Sugaya M, Kadono T, Sato S. Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. PloS One 2012; 7: e34587.
37. Schmidt N, Gonzales E, Visekruna A, et al. Targeting the proteasome; partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010; 59: 896-906.
38. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 2004; 126: 1504-1517.
39. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-181.
40. Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007; 8: 65-71.
41. Zhu Y, Zhao X, Zhu X, et al. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part 1: comprehensive understanding of the SAR of alpha-amino acid boronates. J Med Chem 2009; 52: 4192-4199.
42. Lassmann H. Classification of demyelinating disease at the interface between etiology and pathogenesis. Curr Opin Neurol 2001; 14: 253-258.
43. Wekerle H, Kojima K, Lannes-Vieiria J, Lassmann H, Linington C. Animal models. Ann Neurol 1994; 36 (Supp): S47-S53.
44. Fissolo N, Kraus M, Reich M, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008; 38: 2401-2411.
45. Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 2000; 12: 233-239.
46. Vrolix K, Fraussen J, Molenaar PC, et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010; 43: 380-400.
47. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368.
48. Gomez AM, Vrolix K, Martínez-Martínez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011; 186: 2503-2513.
49. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010; 185: 634-641.
50. Muchamuel T, Basler M, Aujay A, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-787.
51. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
52. Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type 1 interferon and autoantibody-secreting cells. Arthritis Rheum 2012; 64: 493-503.
53. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042-1049.
54. Nagayama Y, Nakahara M, Shimamura M, et al. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol 2012; 168: 268-273.
55. Zanotto-Filho A, Braganhol E, Battastini AMO, Moreira JCF. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Invest New Drugs 2012; doi 10.1007/s10637-012-9804-z.
56. Petrovic J, Hall H, Mehr R, Glas R, Höglund P. Inhibition of the proteasome reduces transfet-induced diabetes in nonobese diabetic mice. Scan J Immunol 2004; 60: 134-142.
57. Kwon G, Corbett JA, Hauser S, et al. Evidence for involvement of the proteasome complex (26S) and NFkappaB in IL-1 beta-induced nitric oxide and prostaglandin production by rat islets and RINm5F cells. Diabetes 1998; 47: 583-591.
58. Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009; 156: 172-182.
59. Ahmed AS, Li J, Ahmed M, et al. Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132. Arthritis Rheum 2010; 62: 2160-2169.
60. Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol 2008; 4: 464-472.
61. Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006; 25: 403-415.
62. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
63. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111: 2765-2775.
64. Ruggeri B, Miknyoczki S, Dorsey B, Hui AM. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Adv Pharmacol 2009; 57:91-135.
65. Berkers CR, Leestemaker Y, Schuurman KG, et al. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Mol Pharm 2012; 9: 1126-1135.
66. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489-2499.
67. Groll M, Berkers CR, Ploegh LH, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14: 451-456.
68. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
69. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005; 8: 407-419.
70. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEED8-activating enxyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
71. Bruzzese FJ, Milhollen MA, Gavin JM, Josephine HR, Brownell JE. Identification and application of NEDD8 E1 inhibitors. In: Ubiquitin family modifiers and the proteasome: reviews and protocols. Methods in Molecular Biology. Ed R. J Dohmen and M. Scheffner: Springer Science+Business Media LLC 2012; Vol 832:pp 577.
72. Xu K, Xiao Z, Tang YB, et al. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. Bioorg Med Chem Lett 2012; 22: 2772-2774.
73. Ge Y, Kazi A, Marsilio F, et al. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J Med Chem 2012; 55: 1978-1998.
74. Ungermannova D, Parker SJ, Nasveschu KCG, et al. Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J Biomol Screen 2012; 17: 421-434.
75. Ahn KS, Sethi G, Chao TH, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through downmodulation of NF-kB regulated gene products. Blood 2007; 110: 2286-2295.
76. Price T, Millward M, Mainwaring P, et al. A 2 arm phase I clinical trial with NPI-0052 (a novel proteasome inhibitor). EORTCAACR-NCI Int Conf Molecular Targets and Cancer Therapeutics.
77. Hofmeister CC, Richardson P, Zimmerman T, et al. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/R MM). J Clin Oncol 2009; 27: 15s.
78. Millward M, Price T, Townsend A, et al. Phase I clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2011; doi10.1007/s10637-011-9766-6.
79. Hancok WW, Akimova T, Beier UH, Liu Y, Wang L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012; 71 (Suppl. 2): 146-154.
80. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 1999; 274: 12036-12042.
81. McMillin DW, Jacobs HM, Delmore J, et al. Molecular and cellular effects of NEED8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012; 11: 942-951.
82. Sasse F, Steinmetz H, Schupp T, et al. Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, phyco-chemical and biological properties. J Antibiot 2002; 55: 543-551.
83. Vollbrecht L, Steinmetz H, Hofle G, et al. Argyrins, immunosuppressive cyclic peptides from myxobacteria. II. Structure elucidation and stereochemistry. J Antibiot 2002; 55: 715-721.
84. Koguchi Y, Kohno J, Nishio M, et al. TMC-95A, B, C, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot 2000; 53: 105-109.
85. Kohno J, Koguchi Y, Nishio M, et al. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J Org Chem 2000; 65: 990-995.
86. Maréchal X, Pujol A, Richy N, et al. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors. Eur J Med Chem 2012; 52: 322-327.
87. Myer S, Kohler NG, Joly A. Cyclosporin A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 1997; 413: 354-358.
88. Krunic A, Vallat A, Mo S, et al. Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii. J Nat Prod 2010; 73: 1927-1932.
89. Groll M, Schellenberg B, Bachmann AS, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008; 452; 755-758.
90. Waspi U, Blanc D, Winkler T, Ruedi P, Dudler R. Syringolin, a novel peptide elicitor from pseudomonas syringae pv. Syringae that induces resistance to Pyricularia oryzae in rice. Mol Plant Microne In 1998; 11: 727-733.
91. Waspi U, Hassa P, Staempfli AA, Molleyres LP, Winkler T, Dudler R. Identification and structure of a family of syringolin variants: unusual cyclic peptides from Pseudomonas syringae that elicit defense responses in rice. Microbiol Res 1999; 154: 89-93.
92. Anshu A, Thomas S, Agarwal P, Ibarra-Rivera TR, Pirrung MC, Schonthal AH. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. Biochem Pharmacol 2010; 80: 170-198.
93. Opoku-Ansah, Ibarra-Rivera TR, Pirrung MC, Bachmann AS. Syringolin B-Inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma. Pharm Biol 2012; 50: 25-29.
94. Oka M, Nishiyama Y, Ohta S, et al. Glidobactins A, B, and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity. J Antibiot 1988; 41: 1331-1337.
95. Terui Y, Nishikawa J, Hinoo H, Kato T, Shoji J. Structures of cepafungins I, II and III. J Antibiot 1990; 43: 788-795.
96. Pandit B, Gartel AL. Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol Ther 2011; 11: 43-47.
97. Kazi A, Lawrence H, Guida WC, et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009; 8: 1940-1951.
98. Dang Z, Lin A, Ho P, et al. Synthesis and proteasome inhibition of lithocolic acid derivatives. Biorg Med Chem Lett 2011; 21: 1926-1928.
99. Dalla Via L, Nardon C, Fregona D. Targeting the ubiquitinproteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Med Chem 2012; 4: 525-543.
100. Chen D, Frezza M, Shakya R, et al. Inhibition of the proteasome activity by gallium (III) complexes contributes to their anti-prostate tumor effects. Cancer Res 2007; 67: 9258-9265.
101. Ronconi L, Aldinucci D, Dou QP, Fregona D. Latest insights into the anticancer activity of Au(III)-dithiocarbamato complexes. Anticancer Agents Med Chem 2010; 10: 283-292.